NDA 221291 · Bayer Healthcare
Sunharbo
Asundexian · Film Coated
NovelPriority reviewCDER novel approval, Nov 9, 2026: To reduce the risk of stroke in adults following a recent mild-to-moderate non-cardioembolic ischemic stroke or a high-risk transient ischemic attack
Last checked: Nov 19, 2026Latest source record: Nov 9, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2026
Nov 9, 2026
Approved uses
1
Original approval plus efficacy supplements
Registered trials
3
2 Phase 3, 0 recruiting
FAERS reports
6
6 serious, 0 with death reported
AI brief across all sources
Written by Claude (Anthropic's AI) from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Nov 9, 2026.
Sunharbo is indicated in combination with antiplatelet therapy to reduce the risk of stroke in adults with recent non-cardioembolic ischemic stroke (NIH Stroke Scale ≤15) or high-risk transient ischemic attack (TIA). SUNHARBO is a factor XIa inhibitor indicated in combination with antiplatelet therapy to reduce the risk of stroke in adults with recent non-cardioembolic ischemic stroke (NIH Stroke Scale ≤15) or high-risk transient ischemic attack (TIA).
Mechanism: Asundexian is an inhibitor of activated factor XI (FXIa). FXIa leads to downstream activation of Factor X, resulting in thrombin generation via the intrinsic pathway. Thrombin activates Factor XI via a positive feedback loop, which leads to an amplification of thrombus formation and stability. FXIa inhibition reduces amplification of thrombin generation.
Therapeutic areas: Cardiovascular and metabolic
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Nov 9, 2026 Original approval · Type 1 - New Molecular Entity · priority review NovelLetter
1 products under this application
- SUNHARBO · ASUNDEXIAN 50MG · TABLET, FILM COATED · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Asundexian" as an intervention, any sponsor and status, largest first.
BayerBayer (BAYRY)
NCT05643573 · 14,830 participants · Start Dec 5, 2022 · Primary completion Jan 31, 2024
Drug: Asundexian (BAY2433334); Apixaban and 2 more · For: Prevention of Stroke or Systemic Embolism; Atrial Fibrillation
Sites: Dothan, Alabama; Fairhope, Alabama; Mobile, Alabama · 1,069 sites in all
- A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After a High-risk Transient Ischemic Attack, a So-called Mini StrokePivotal-lookingCompleted
BayerBayer (BAYRY)
NCT05686070 · 12,327 participants · Start Jan 26, 2023 · Primary completion Oct 23, 2025
Drug: Asundexian (BAY2433334); Placebo · For: Prevention of Ischemic Stroke; Acute Non-cardioembolic Ischemic Stroke; High-risk Transient Ischemic Attack
Sites: Fairhope, Alabama; Phoenix, Arizona; Scottsdale, Arizona · 741 sites in all
BayerBayer (BAYRY)
NCT05419635 · 27 participants · Start Jun 14, 2022 · Primary completion May 24, 2023
Drug: Asundexian (BAY2433334) · For: Prevention of Thromboembolic Events; Atrial Fibrillation; Acute Myocardial Infarction and 2 more
Sites: Kiel, Germany
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- upper gastrointestinal haemorrhage3
- abdominal pain2
- pancreatitis necrotising2
- splenic vein thrombosis2
- colon cancer1
- duodenal ulcer haemorrhage1
- lower gastrointestinal haemorrhage1
- procedural complication1
- procedural haemorrhage1
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2023 | 1 |
| 2024 | 2 |
| 2025 | 3 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Asundexian for Secondary Stroke Prevention.
Sharma M, Dong Q, Hirano T, et al. · N Engl J Med 2026 · Randomized Controlled Trial, Clinical Trial, Phase III
- Asundexian versus Apixaban in Patients with Atrial Fibrillation.
Piccini JP, Patel MR, Steffel J, et al. · N Engl J Med 2025 · Clinical Trial, Phase III, Equivalence Trial
- Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study.
Piccini JP, Caso V, Connolly SJ, et al. · Lancet 2022 · Clinical Trial, Phase II, Multicenter Study
- No Influence of Asundexian on Cardiac Repolarization.
Brase C, Kanefendt F, Loewen S, et al. · Clin Pharmacol Drug Dev 2024 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Asundexian or Apixaban in Patients With Atrial Fibrillation According to Prior Oral Anticoagulant Use: A Subgroup Analysis of the OCEANIC-AF Randomized Clinical Trial.
Alexander JH, Lydon EJ, Piccini JP, et al. · JAMA Cardiol 2025 · Clinical Trial, Phase III, Multicenter Study
- Factor XIa inhibition with asundexian after acute non-cardioembolic ischaemic stroke (PACIFIC-Stroke): an international, randomised, double-blind, placebo-controlled, phase 2b trial.
Shoamanesh A, Mundl H, Smith EE, et al. · Lancet 2022 · Randomized Controlled Trial
Sponsor: Bayer
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.